Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

Modern Cancer Treatments Are Writing the True Story of History.. The Shining Three Musketeers of Cancer Treatment: Ipilimumab (Athos), Nivolumab (Porthos), Pembrolizumab (Aramis)

Modern Cancer Treatments Are Writing the True Story of History.. The Shining Three Musketeers of Cancer Treatment: Ipilimumab (Athos), Nivolumab (Porthos), Pembrolizumab (Aramis)

Alexandre Dumas left his mark on minds and hearts with the heroes he created by taking the history of an era beyond reality. With new molecules recalling this trio and even D'Artagnan, these new developments in cancer seem to tell Dumas: we are writing a genuine success story in the spirit of the Three Musketeers.

Let us look together at what these new treatments are and the ray of hope they offer our patients.

For nearly 100 years, studies in cancer treatment targeted methods that directly kill cancer cells. Yet the power of the immune system, one of the body's most important self-protective mechanisms, was ignored, or its inadequacy was attributed to the strength of cancer cells. Our immune system is like a double-edged sword. When it functions excessively and uncontrollably, diseases involving damage to various organs develop, which we can describe as immune overactivity. When it functions inadequately, adverse conditions arise, ranging from infections to a predisposition to cancer.

While scientists in the 1990s were losing hope of developing immune-mediated drugs to fight cancer, Prof. James Allison was among those who did not lose hope. While serving as director of the UC Berkeley Cancer Research Laboratory in the late 1990s, Allison became interested in a particular biological molecule called CTLA-4. Allison and colleagues demonstrated that this molecule, present on T cells, the immune system's most important cells, acts by braking (inhibiting) T-cell activity. T cells were known to play a critical role in organizing immune attacks. Wondering how removing this inhibition might benefit cancer treatment, the trio began working in mouse cancer models. In an article published in 1996, Jim Allison, Max Krummel, and Dana Leach showed that tumor growth could be eliminated in mice in which CTLA-4 activation was blocked by an antibody. This study inspired groundbreaking new drugs developed and known as immune checkpoint regulators. Following this development, a drug called ipilimumab (YERVOY), a type of antibody with CTLA-4-blocking properties (similar to a vaccine), was used in patients with advanced malignant melanoma, an extremely aggressive skin cancer. Successful in early human clinical trials, YERVOY was shown to contribute significantly to survival in advanced (metastatic) malignant melanoma. The successful results were published in 2010 in the New England Journal of Medicine, one of the most respected scientific journals.

Following targeted drugs developed against cancer cells, this study brought a new revolution and a success story. Based on this knowledge, new braking mechanisms were identified that could mobilize the knocked-out immune system in cancer patients. PD-1, also known as programmed cell death protein, is a receptor on the cell surface. A protein ligand called PD-L1 binds to this receptor and activates the immune system's braking mechanism against cancer. Two drugs developed against these protein structures, nivolumab (Opdivo) and pembrolizumab (Keytruda), were proven effective not only in malignant melanoma but also in another extremely difficult-to-manage cancer, lung cancer. This journey in cancer treatment, which began with ipilimumab and continues with these two new antibody drugs developed against the PD-1 receptor, reminded me of the mark the Three Musketeers left in hearts and memories. This promising journey, which began in skin and lung cancer, appears set to continue in other cancer types.

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

Modern Cancer Treatments Are Writing the True Story of History.. The Shining Three Musketeers of Cancer Treatment: Ipilimumab (Athos), Nivolumab (Porthos), Pembrolizumab (Aramis)

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy